{"id":6916,"date":"2025-05-22T12:10:10","date_gmt":"2025-05-22T09:10:10","guid":{"rendered":"https:\/\/jordan-cardiac.org\/?p=6916"},"modified":"2025-05-22T12:10:10","modified_gmt":"2025-05-22T09:10:10","slug":"from-pci-mena-af-atrial-flutter-ablation-class-of-recommendation","status":"publish","type":"post","link":"https:\/\/jordan-cardiac.org\/en\/from-pci-mena-af-atrial-flutter-ablation-class-of-recommendation\/","title":{"rendered":"From PCI MENA \u2013 AF &#038; Atrial Flutter Ablation: Class of Recommendation"},"content":{"rendered":"<div>From PCI MENA \u2013 AF &amp; Atrial Flutter Ablation: Class of Recommendation<\/div>\n<div>(Based on EHRA\/EAPCI Consensus Documents)<\/div>\n<div><span> \u2022 AF Ablation<\/span><\/div>\n<div>\u2022 Class I: Symptomatic paroxysmal AF, failed \u22651 AAD(AAD stands for Antiarrhythmic Drug).<\/div>\n<div>\u2022 Class IIa: Persistent AF or first-line in selected patients<\/div>\n<div>\u2022 Class IIb: Asymptomatic or HF patients (selectively)<\/div>\n<div><span> \u2022 Atrial Flutter Ablation<\/span><\/div>\n<div>\u2022 Class I: First-line for typical (CTI-dependent) flutter<\/div>\n<div><span> \u2022 AF Ablation in HFrEF<\/span><\/div>\n<div>\u2022 Class IIa: May reduce mortality\/hospitalizations (CASTLE-AF)<\/div>\n<div>Summary:<\/div>\n<div><span> \u2022 AF ablation decisions depend on symptoms, drug failure, and patient profile<\/span><\/div>\n<div><span> \u2022 Atrial Flutter ablation is more straightforward: first-line regardless of symptoms.<\/span><\/div>\n<div>Summary \u2013 Treatment Pathway<\/div>\n<div><span> 1. First presentation \u2013 Paroxysmal AF<\/span><\/div>\n<div>\u2022 Lifestyle changes + rate control<\/div>\n<div>\u2022 If symptoms persist \u2192 rhythm control<\/div>\n<div>\u2022 If drug fails \u2192 ablation (Class I)<\/div>\n<div><span> 2. Persistent AF<\/span><\/div>\n<div>\u2022 Try medications first<\/div>\n<div>\u2022 If failure or in selected cases \u2192 ablation (Class IIa)<\/div>\n<div><span> 3. Asymptomatic or Heart Failure patients<\/span><\/div>\n<div>\u2022 Consider ablation selectively (Class IIb)<\/div>\n<div>\u2022 Especially in HFrEF based on CASTLE-AF trial.<\/div>\n<div>\u2022 \u2060Left atrial size plays a key role in AF management. Patients with a normal or mildly enlarged left atrium (\u22644.0 cm in men, \u22643.8 cm in women) tend to have better outcomes after ablation, especially in paroxysmal AF. In contrast, a left atrial diameter &gt;4.6\u20135.2 cm suggests more advanced disease, is more common in persistent AF, and may lead to lower success rates after ablation. Therefore, measuring LA size by echocardiography helps guide treatment decisions and patient selection.<\/div>\n","protected":false},"excerpt":{"rendered":"<p>From PCI MENA \u2013 AF &amp; Atrial Flutter Ablation: Class of Recommendation (Based on EHRA\/EAPCI Consensus Documents) \u2022 AF Ablation \u2022 Class I: Symptomatic paroxysmal AF, failed \u22651 AAD(AAD stands for Antiarrhythmic Drug). \u2022 Class IIa: Persistent AF or first-line in selected patients \u2022 Class IIb: Asymptomatic or HF patients (selectively) \u2022 Atrial Flutter Ablation [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-6916","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/6916","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/comments?post=6916"}],"version-history":[{"count":1,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/6916\/revisions"}],"predecessor-version":[{"id":6917,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/6916\/revisions\/6917"}],"wp:attachment":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/media?parent=6916"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/categories?post=6916"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/tags?post=6916"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}